2.50
Hdl Handle:
http://hdl.handle.net/10547/601102
Title:
Analogue peptides for the immunotherapy of human acute myeloid leukemia
Authors:
Hofmann, Susanne; Mead, Andrew; Malinovskis, Aleksandrs; Hardwick, Nicola R.; Guinn, Barbara-Ann
Abstract:
The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials. However, responses are often short-lived and rarely induce notable memory responses. The reason is that self-antigens have already been presented to the immune system as the tumor develops, leading to tolerance or some degree of host tumor cell destruction. To try to break tolerance against self-antigens, one of the methods employed has been to modify peptides at the anchor residues to enhance their ability to bind major histocompatibility complex molecules, extending their exposure to the T-cell receptor. These modified or analogue peptides have been investigated as stimulators of the immune system in patients with different cancers with variable but sometimes notable success. In this review we describe the background and recent developments in the use of analogue peptides for the immunotherapy of acute myeloid leukemia describing knowledge useful for the application of analogue peptide treatments for other malignancies.
Affiliation:
University of Bedfordshire
Citation:
Hofmann, S., Mead, A., Malinovskis, A., Hardwick, N.R., Guinn B. (2015) 'Analogue peptides for the immunotherapy of human acute myeloid leukemia'. Cancer Immunology, Immunotherapy 64 (11):1357-67
Publisher:
Springer
Journal:
Cancer Immunology, Immunotherapy
Issue Date:
5-Oct-2015
URI:
http://hdl.handle.net/10547/601102
DOI:
10.1007/s00262-015-1762-9
Additional Links:
http://link.springer.com/10.1007/s00262-015-1762-9
Type:
Article
Language:
en
Description:
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9
ISSN:
0340-7004; 1432-0851
Sponsors:
Dr Susanne Hofmann received funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) and Drs Nicola Hardwick and Barbara Guinn from Leukaemia and Lymphoma Research.
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorHofmann, Susanneen
dc.contributor.authorMead, Andrewen
dc.contributor.authorMalinovskis, Aleksandrsen
dc.contributor.authorHardwick, Nicola R.en
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2016-03-10T10:41:40Zen
dc.date.available2016-03-10T10:41:40Zen
dc.date.issued2015-10-05en
dc.identifier.citationHofmann, S., Mead, A., Malinovskis, A., Hardwick, N.R., Guinn B. (2015) 'Analogue peptides for the immunotherapy of human acute myeloid leukemia'. Cancer Immunology, Immunotherapy 64 (11):1357-67en
dc.identifier.issn0340-7004en
dc.identifier.issn1432-0851en
dc.identifier.doi10.1007/s00262-015-1762-9en
dc.identifier.urihttp://hdl.handle.net/10547/601102en
dc.descriptionAccepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9en
dc.description.abstractThe use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials. However, responses are often short-lived and rarely induce notable memory responses. The reason is that self-antigens have already been presented to the immune system as the tumor develops, leading to tolerance or some degree of host tumor cell destruction. To try to break tolerance against self-antigens, one of the methods employed has been to modify peptides at the anchor residues to enhance their ability to bind major histocompatibility complex molecules, extending their exposure to the T-cell receptor. These modified or analogue peptides have been investigated as stimulators of the immune system in patients with different cancers with variable but sometimes notable success. In this review we describe the background and recent developments in the use of analogue peptides for the immunotherapy of acute myeloid leukemia describing knowledge useful for the application of analogue peptide treatments for other malignancies.en
dc.description.sponsorshipDr Susanne Hofmann received funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) and Drs Nicola Hardwick and Barbara Guinn from Leukaemia and Lymphoma Research.en
dc.language.isoenen
dc.publisherSpringeren
dc.relation.urlhttp://link.springer.com/10.1007/s00262-015-1762-9en
dc.rightsArchived with thanks to Cancer Immunology, Immunotherapyen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectanalogue peptidesen
dc.subjectadult acute myeloid leukemiaen
dc.subjectclinical trialsen
dc.subjectPASD1en
dc.subjectheteroclitic peptidesen
dc.subjectNPM1en
dc.subjectpeptidesen
dc.subjectimmunotherapyen
dc.subjectC550 Immunologyen
dc.titleAnalogue peptides for the immunotherapy of human acute myeloid leukemiaen
dc.typeArticleen
dc.contributor.departmentUniversity of Bedfordshireen
dc.identifier.journalCancer Immunology, Immunotherapyen
This item is licensed under a Creative Commons License
Creative Commons
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.